The Development Pathway and Growing Adoption of Biosimilars: Increasing Access to Essential Biological Therapies in
Biosimilars are biological medicinal products that are highly similar to an already approved reference biological product, in terms of structure, biological activity, efficacy, and safety profile. Unlike chemically synthesized small-molecule drugs, biological agents are derived from living systems and are inherently complex, meaning a biosimilar is not an identical copy, but a close, functional equivalent.
The development process for these agents is exceptionally rigorous, requiring extensive comparative analytical, non-clinical, and clinical data to demonstrate that any minor differences from the original product are not clinically meaningful. This stringent review process ensures that patients receive a therapeutic agent with an equivalent clinical outcome for its approved indications.
Biological therapies, which include large molecules like proteins, hormones, and monoclonal antibodies, have revolutionized the management of complex, chronic conditions such as rheumatoid arthritis, inflammatory bowel disease, and various cancers. However, the high cost of the originator products has historically limited their accessibility. The…